Kymera Therapeutics (NASDAQ:KYMR) Insider Noah Goodman Sells 5,000 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Noah Goodman sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $114.00, for a total value of $570,000.00. Following the sale, the insider directly owned 50,195 shares in the company, valued at approximately $5,722,230. The trade was a 9.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Noah Goodman also recently made the following trade(s):

• On Monday, June 22nd, Noah Goodman sold 2,500 shares of Kymera Therapeutics stock. The shares were sold at an average price of $99.00, for a total value of $247,500.00.
• On Tuesday, April 14th, Noah Goodman sold 1,347 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.00, for a total value of $121,230.00.
• On Friday, April 10th, Noah Goodman sold 2,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $87.35, for a total value of $174,700.00.
• On Thursday, April 9th, Noah Goodman sold 8,264 shares of Kymera Therapeutics stock. The shares were sold at an average price of $87.50, for a total value of $723,100.00.

Kymera Therapeutics Stock Up 16.6%

Shares of KYMR stock opened at $116.46 on Friday. The stock has a 50-day simple moving average of $84.43 and a 200 day simple moving average of $82.12. Kymera Therapeutics, Inc. has a fifty-two week low of $36.65 and a fifty-two week high of $130.05. The stock has a market capitalization of $9.58 billion, a P/E ratio of -32.62 and a beta of 2.02.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The firm had revenue of $34.37 million for the quarter, compared to analysts’ expectations of $8.27 million. During the same period in the previous year, the business earned ($0.82) earnings per share. Kymera Therapeutics’s revenue for the quarter was up 55.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -3.25 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of KYMR. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Kymera Therapeutics by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock valued at $849,000 after acquiring an additional 1,833 shares in the last quarter. Millennium Management LLC lifted its position in shares of Kymera Therapeutics by 340.4% in the first quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock worth $13,972,000 after purchasing an additional 394,562 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Kymera Therapeutics by 121.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock worth $24,535,000 after purchasing an additional 491,737 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of Kymera Therapeutics by 13.8% during the second quarter. Invesco Ltd. now owns 47,884 shares of the company’s stock worth $2,090,000 after purchasing an additional 5,809 shares during the period. Finally, Sei Investments Co. purchased a new position in Kymera Therapeutics during the second quarter valued at approximately $265,000.

Analyst Ratings Changes

A number of brokerages have recently commented on KYMR. Citigroup increased their price objective on Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Jefferies Financial Group assumed coverage on Kymera Therapeutics in a report on Monday, March 16th. They issued a “buy” rating and a $110.00 target price on the stock. UBS Group upped their target price on Kymera Therapeutics from $90.00 to $128.00 and gave the company a “buy” rating in a report on Tuesday, March 3rd. Loop Capital set a $97.00 price target on Kymera Therapeutics in a research report on Monday, June 8th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $119.00 price target on shares of Kymera Therapeutics in a research note on Thursday, April 30th. One analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Kymera Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $117.14.

Kymera Therapeutics News Roundup

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera announced that enrollment in its Phase 2b BROADEN2 trial of KT-621 for moderate to severe atopic dermatitis was completed nearly six months ahead of schedule, with topline data expected by year-end 2026. The accelerated timeline also supports the company’s broader development plans for KT-621, including a planned Phase 3 start by mid-2027. Article: Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
• Positive Sentiment: BTIG Research reaffirmed its buy rating and set a $134 price target, implying additional upside if the clinical program continues to progress. Article: Kymera Therapeutics Stock Climbs On Accelerated Timeline For Lead Atopic Dermatitis Program
• Neutral Sentiment: The company also announced Felix J. Baker, Ph.D. as chairman of the board, a leadership change that may help support oversight but is less likely to move the stock on its own. Article: Kymera Therapeutics Appoints Felix J. Baker, Ph.D.
• Negative Sentiment: Insider Noah Goodman sold 5,000 shares at $114 each, which can sometimes be viewed as a cautious signal, though the sale was relatively small versus his remaining holdings. Article: Insider transaction filing

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.